BENRALIZUMAB (Fasenra) prior authorization at Point32Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Point32Health requires Interleukin-5 Receptor alpha-directed Cytolytic Antibody prior-authorization documentation for BENRALIZUMAB (Fasenra): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Point32Health reviews BENRALIZUMAB (Fasenra) prior authorizations against its medical policy for Interleukin-5 Receptor alpha-directed Cytolytic Antibody. Point32Health-specific context: Formed by 2021 merger of Tufts Health Plan and Harvard Pilgrim Health Care; ~2M members across New England. Brands operate separately (Harvard Pilgrim, Tufts Health Plan). MA DOI primary regulator; MA OPP external review applies in Massachusetts.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-5 Receptor alpha-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Point32Health's medical policy URL referenced in the cover letter
Point32Health's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy)
- MA mandated benefit disputes
- Specialty drug PA
- Behavioral health prior auth
BENRALIZUMAB (Fasenra)-specific denial patterns and context
Across payers (not just Point32Health), BENRALIZUMAB (Fasenra)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Eosinophil count threshold (≥300 cells/µL within 12 months)
- Step therapy requiring mepolizumab first within IL-5 class
- Indication restriction (severe asthma vs EGPA — December 2024)
Brand: Fasenra. IL-5 receptor α monoclonal antibody. Approved for severe eosinophilic asthma; expanded to eosinophilic granulomatosis with polyangiitis (EGPA) September 2024.
Manufacturer patient-assistance program: Benra360 Patient Support — relevant when a Point32Health denial sticks and the patient needs bridge access while appealing.
How Point32Health approaches Biologic drugs (mAbs and biosimilars) PAs
Point32Health's Biologic drugs (mAbs and biosimilars) reviewer typically anchors BENRALIZUMAB (FASENRA) prior-auth decisions on specialty drug pa. Pharmacy-benefit review for BENRALIZUMAB (FASENRA) at Point32Health is routed through Express Scripts (Harvard Pilgrim and Tufts Health Plan brands). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Point32Health's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Point32Health is domiciled in MA, so unresolved appeals escalate to the MA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Formed by 2021 merger of Tufts Health Plan and Harvard Pilgrim Health Care; ~2M members across New England.
If the PA is denied
Point32Health gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.point32health.org/providers) with the same packet plus a peer-reviewed citation supporting BENRALIZUMAB (Fasenra)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Point32Health denial on DenialHelp.
Contact Point32Health
- Provider portal: https://www.point32health.org/providers
Frequently asked questions
What documentation does Point32Health need for BENRALIZUMAB (Fasenra) prior auth?
Point32Health's typical PA packet for BENRALIZUMAB (Fasenra): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-5 Receptor alpha-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Point32Health?
Standard BENRALIZUMAB (Fasenra) PA decisions at Point32Health: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Point32Health most often reject BENRALIZUMAB (Fasenra) for?
Across Point32Health's book the common rejection patterns include: Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy); MA mandated benefit disputes; Specialty drug PA. For BENRALIZUMAB (Fasenra) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Point32Health typically require before approving BENRALIZUMAB (FASENRA)?
Point32Health's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For BENRALIZUMAB (FASENRA), attach the specific disease-activity instrument Point32Health accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts (Harvard Pilgrim and Tufts Health Plan brands). External-review escalation for Point32Health fully-insured policies sits with the MA insurance department.
How do I prep for a peer-to-peer with Point32Health on BENRALIZUMAB (Fasenra)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the BENRALIZUMAB (Fasenra) PA packet
Open ApprovalHelp — generate a BENRALIZUMAB (Fasenra) prior-auth packet tailored to Point32Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com